Lawrence D. Mayer, Ph.D.

AIMBE College of Fellows Class of 2015
For outstanding contributions to the field of nanomedicines and the development of novel pharmaceutical products for cancer and other diseases

Celator Parlays Leukemia Drug Data into $1.5B Buyout From Jazz Pharma

Via Xconomy | May 31, 2016

All it takes to become an acquisition target in biotech is some promising data. Take Ewing, NJ, and Vancouver-based Celator Pharmaceuticals, which Jazz Pharmaceuticals just agreed to buy this morning for $1.5 billion.

Celator (NASDAQ: CPXX) was formed in 1999 by a team led by Lawrence Mayer and Marcel Bally, both veterans of the British Columbia Cancer Agency. The company went public in 2013, and its shares subsequently hovered between $1 and $5 apiece for more than two years. Then in this March, Celator’s CPX-351—a reformulation of the chemotherapy combination of cytarabine and daunorubicin, which is often used to treat acute myeloid leukemia—helped extend patients’ lives in a Phase 3 trial. Shares zoomed from $1.53 apiece to $8.70 in a day, then a record high, and have kept climbing. Now Jazz will pay $30.25 a share in cash, or $1.5 billion, for Celator and its AML drug.

Celator was to file for approval of CPX-351, known as Vyxeos, in the U.S. and Europe later this year. But developing a drug is completely different from successfully launching and selling it, and the latter is often best suited for companies with those capabilities already in place. Enter Jazz (NASDAQ: JAZZ). The Dublin-based firm is best known for the narcolepsy drug sodium oxybate (Xyrem), but has a presence in cancer, with the leukemia drug asparaginase Erwinia chrysanthemi (Erwinase), and hematology, with defibrotide sodium (Defitelio). Jazz will use its existing sales force to help carry CPX-351 to the finish line.

“We believe that Jazz Pharmaceuticals’ clinical and commercial expertise in hematology/oncology and existing international infrastructure will help realize the value of [CPX-351] as a treatment to patients with AML,” said Celator CEO Scott Jackson, in a statement. “After thoroughly evaluating our strategic options, our board of directors has unanimously determined that this all-cash transaction is in the best interest of our stockholders.”

Celators New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer [CPXX] – The Life Sciences Report

Via Life Sciences Report | April 22, 2015

Celator Pharmaceuticals Inc.’s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company’s CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.

Lawrence D. Mayer, Ph.D. To be Inducted into Medical and Biological Engineering Elite

Via AIMBE | March 5, 2015

WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Lawrence D. Mayer, Ph.D., Founder, President and Chief Scientific Officer, , Celator Pharmaceuticals, to its College of Fellows. Dr. Mayer was nominated, reviewed, and elected by peers and members of the College of Fellows For outstanding contributions to the field of nanomedicines and the development of novel pharmaceutical products for cancer and other diseases.